Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Encapsulation of therapeutic cells can increase its efficacy, but current methods are non-uniform and inefficient. This inconsistency leads to varying interactions between each encapsulated cell and the extracellular matrix (ECM).